Literature DB >> 12516557

The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors.

Pablo A Silveira1, Ellis Johnson, Harold D Chapman, Thi Bui, Roland M Tisch, David V Serreze.   

Abstract

B lymphocytes partially contribute to autoimmune type 1 diabetes (T1D) as a subset of APC with a preferential ability to trigger pathogenic CD4 T cells. We hypothesized that this resulted from the unique ability of B lymphocytes to take up pancreatic beta cell proteins through Ig mediated capture. T1D was significantly delayed, but not prevented, in a NOD stock in which the B lymphocyte Ig repertoire was strongly restricted because of the allelic exclusion induced by transgenic Ig molecules specific for the disease irrelevant hen egg lysozyme (HEL) protein (NOD.IgHEL mice). However, introducing the Ig(mu)null mutation to eliminate the small residual numbers of non-transgenic B lymphocytes in the NOD.IgHEL stock strongly suppressed T1D to the same low levels that characterize B lymphocyte deficient NOD.Ig(mu)null mice. In contrast to standard NOD mice, both the NOD.IgHEL.Ig(mu)null and NOD.Ig(mu)null stocks were unable to generate T cell responses against the candidate diabetes autoantigen, glutamic acid decarboxylase. These results indicate that Ig-mediated capture of beta cell autoantigens accounts for why B lymphocytes have a greater capacity than other APC subtypes to trigger diabetogenic T cells. Hence, defects in B lymphocyte, as well as T lymphocyte, tolerance induction mechanisms may contribute to T1D in NOD mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516557     DOI: 10.1002/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  66 in total

Review 1.  Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.

Authors:  C Hu; F S Wong; L Wen
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

2.  Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene.

Authors:  Peggy L Kendall; Daniel J Moore; Chrys Hulbert; Kristen L Hoek; Wasif N Khan; James W Thomas
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

Review 3.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

Review 4.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

5.  The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Authors:  Alexandra I Ziegler; Melanie A Le Page; Mhairi J Maxwell; Jessica Stolp; Haoyao Guo; Abhirup Jayasimhan; Margaret L Hibbs; Pere Santamaria; Jacques F Miller; Magdalena Plebanski; Pablo A Silveira; Robyn M Slattery
Journal:  Diabetologia       Date:  2013-09-08       Impact factor: 10.122

6.  Alpha4beta7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice.

Authors:  Baohui Xu; Rachel E Cook; Sara A Michie
Journal:  J Autoimmun       Date:  2010-05-21       Impact factor: 7.094

7.  Subcongenic analyses reveal complex interactions between distal chromosome 4 genes controlling diabetogenic B cells and CD4 T cells in nonobese diabetic mice.

Authors:  Jessica Stolp; Yi-Guang Chen; Selwyn L Cox; Vivien Henck; Wenyu Zhang; Shirng-Wern Tsaih; Harold Chapman; Timothy Stearns; David V Serreze; Pablo A Silveira
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

8.  Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.

Authors:  Andreas Wieland; Rangaiah Shashidharamurthy; Alice O Kamphorst; Jin-Hwan Han; Rachael D Aubert; Biswa P Choudhury; Sean R Stowell; Junghwa Lee; George A Punkosdy; Mark J Shlomchik; Periasamy Selvaraj; Rafi Ahmed
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

9.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

10.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.